Allon Fulfills Enrollment for Advance Clinical Trial of Davunetide in PSP

Allon Therapeutics has completed patient enrollment ahead of schedule for its phase 2/3 clinical trial to evaluate its lead candidate Davunetide as a potential treatment for progressive supranuclear palsy (PSP). Davunetide’s mechanism of action is relevant to other neurodegenerative diseases, including ALS, as the peptide is believed to influence microtubule stabilization, a process not only relevant to the so-called tauopathies but to other diseases adversely influencing axonal transport. Allon believes that proof of clinical efficacy for PSP would inform future use of davunetide for other neurodegenerative diseases.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail